38 Stocks Moving In Friday’s Mid-Day Session
Gainers
Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 175% to $17.33. Regencell Bioscience reported partial exercise of underwriter’s over-allotment option.
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
10 Biggest Price Target Changes For Friday
Raymond James boosted the price target on The Estée Lauder Companies Inc. (NYSE: EL) from $355 to $375. Estée Lauder shares rose 0.1% to $327.75 in pre-market trading.
Goldman Sachs Downgrades Intercept Pharmaceuticals to Sell, Lowers Price Target to $10
Goldman Sachs analyst Salveen Richter downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Neutral to Sell and lowers the price target from $17 to $10.
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Return on Capital Employed Overview: Intercept Pharmaceuticals
After pulling data from Benzinga Pro it seems like during Q2, Intercept Pharmaceuticals (NASDAQ:ICPT) earned $760.00 thousand, a 102.59% increase from the preceding quarter.
HC Wainwright & Co. Maintains Neutral on Intercept Pharmaceuticals, Lowers Price Target to $18
HC Wainwright & Co. analyst Ed Arce maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Neutral and lowers the price target from $21 to $18.
RBC Capital Maintains Sector Perform on Intercept Pharmaceuticals, Raises Price Target to $23
RBC Capital analyst Brian Abrahams maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Sector Perform and raises the price target from $22 to $23.